 NEW YORK, NY ACCESSWIRE April 21, 2021 Kadmon Holdings, Inc. NASDAQ:KDMN today announced the publication of results from KD025-208, the Phase 2a clinical trial of belumosudil KD025 for chronic graft-versus-host disease cGVHD. The results were published in the Journal of Clinical Oncology. 